BACKGROUND: With the growing numbers of liver transplant recipients, it is increasingly important to understand the risks of de novo malignancy after liver transplantation. AIM: To characterize the incidence of de novo malignancy after liver transplantation compared with a control non-transplant population. METHODS: We studied 534 Indiana state residents undergoing liver transplantation at our center between 1997 and 2004, followed through August 2010. The incidence and predictors of malignancy were determined. The standardized incidence ratio (SIR) of cancer in our cohort was compared with age-, gender-, and period-matched state population using the Indiana State Cancer Registry. RESULTS: After a mean follow-up of 5.7 ± 3.2 yr, 73 patients (13.7%) developed 80 cancers, with five- and 10-yr incidence rates of 11.7% and 24.8%, respectively. These included 24 (30%) skin, 16 (20%) hematologic, and 40 (50%) solid tumors. The most common solid cancers were aerodigestive. Compared with matched state population, liver transplant recipients had significantly higher incidence of all cancers (SIR: 3.1, 95% CI [Confidence interval]: 2.9-3.2), skin (melanoma) (SIR: 5.8, 95% CI: 4.7-7.0), hematologic (SIR: 7.1, 95% CI: 6.3-8.0), and solid (SIR: 2.7, 95% CI: 2.5-2.8) tumors. CONCLUSION: There is a significantly increased risk of de novo malignancies after liver transplantation, highlighting the need for surveillance strategies in this population.
BACKGROUND: With the growing numbers of liver transplant recipients, it is increasingly important to understand the risks of de novo malignancy after liver transplantation. AIM: To characterize the incidence of de novo malignancy after liver transplantation compared with a control non-transplant population. METHODS: We studied 534 Indiana state residents undergoing liver transplantation at our center between 1997 and 2004, followed through August 2010. The incidence and predictors of malignancy were determined. The standardized incidence ratio (SIR) of cancer in our cohort was compared with age-, gender-, and period-matched state population using the Indiana State Cancer Registry. RESULTS: After a mean follow-up of 5.7 ± 3.2 yr, 73 patients (13.7%) developed 80 cancers, with five- and 10-yr incidence rates of 11.7% and 24.8%, respectively. These included 24 (30%) skin, 16 (20%) hematologic, and 40 (50%) solid tumors. The most common solid cancers were aerodigestive. Compared with matched state population, liver transplant recipients had significantly higher incidence of all cancers (SIR: 3.1, 95% CI [Confidence interval]: 2.9-3.2), skin (melanoma) (SIR: 5.8, 95% CI: 4.7-7.0), hematologic (SIR: 7.1, 95% CI: 6.3-8.0), and solid (SIR: 2.7, 95% CI: 2.5-2.8) tumors. CONCLUSION: There is a significantly increased risk of de novo malignancies after liver transplantation, highlighting the need for surveillance strategies in this population.
Authors: Edmund Q Sanchez; Shigeru Marubashi; Ghapjoong Jung; Marlon F Levy; Robert M Goldstein; Ernesto P Molmenti; Carlos G Fasola; Thomas A Gonwa; Linda W Jennings; Barbara K Brooks; Goran B Klintmalm Journal: Liver Transpl Date: 2002-03 Impact factor: 5.799
Authors: J Pruthi; K A Medkiff; K T Esrason; J A Donovan; E M Yoshida; S R Erb; U P Steinbrecher; T L Fong Journal: Liver Transpl Date: 2001-09 Impact factor: 5.799
Authors: X Xiol; J Guardiola; S Menendez; C Lama; J Figueras; J Marcoval; T Serrano; J M Botargues; M Mañer; R Rota Journal: Liver Transpl Date: 2001-11 Impact factor: 5.799
Authors: A Joseph Tector; Jonathan A Fridell; Richard S Mangus; Ashesh Shah; Martin Milgrom; Paul Kwo; Naga Chalasani; Hwan Yoo; Dale Rouch; Suthat Liangpunsakul; Scott Herring; Lawrence Lumeng Journal: Liver Transpl Date: 2004-03 Impact factor: 5.799
Authors: C Jiménez; E Marqués; C Loinaz; D R Romano; R Gómez; J C Meneu; G Hernández-Vallejo; O Alonso; M Abradelo; I Garcia; E Moreno Journal: Transplant Proc Date: 2003-08 Impact factor: 1.066
Authors: J Ignacio Herrero; Juan Felipe Lucena; Jorge Quiroga; Bruno Sangro; Fernando Pardo; Fernando Rotellar; Javier Alvárez-Cienfuegos; Jesús Prieto Journal: Am J Transplant Date: 2003-11 Impact factor: 8.086
Authors: Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin Journal: JAMA Date: 2011-11-02 Impact factor: 157.335
Authors: Christophe Carenco; Stéphanie Faure; José Ursic-Bedoya; Astrid Herrero; Georges Philippe Pageaux Journal: World J Gastroenterol Date: 2016-01-07 Impact factor: 5.742